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Abstract
Background: Heart failure (HF) is a highly prevalent chronic disease, for which there is no cure available. Therefore,
improving disease management is crucial, with mobile health (mHealth) being a promising technology. The aim of
the HeartMan study is to evaluate the effect of a personal mHealth system on top of standard care on disease
management and health-related quality of life (HRQoL) in HF.
Methods: HeartMan is a randomized controlled 1:2 (control:intervention) proof-of-concept trial, which will enrol 120 stable
ambulatory HF patients with reduced ejection fraction across two European countries. Participants in the intervention
group are equipped with a multi-monitoring health platform with the HeartMan wristband sensor as the main
component. HeartMan provides guidance through a decision support system on four domains of disease management
(exercise, nutrition, medication adherence and mental support), adapted to the patient’s medical and psychological profile.
The primary endpoint of the study is improvement in self-care and HRQoL after a six-months intervention. Secondary
endpoints are the effects of HeartMan on: behavioural outcomes, illness perception, clinical outcomes and mental state.
Discussion: HeartMan is technologically the most innovative HF self-management support system to date. This trial will
provide evidence whether modern mHealth technology, when used to its full extent, can improve HRQoL in HF.
Trial registration: This trial has been registered on https://clinicaltrials.gov/ct2/show/NCT03497871, on April 13 2018
with registration number NCT03497871.
Keywords: mHealth, Disease management, Heart failure, Health-related quality of life, Decision support system
Background
About 1–2% of people in the western world suffer from
heart failure (HF) [1]. Although treatment improvements
have decreased the number of hospitalizations and
deaths due to HF, the burden remains high with half of
the HF patients being expected to die within five years
after diagnosis, and HF being the most frequent cause of
hospitalization in people aged over 65 [2].
Since there is presently no cure available, a better
management of HF is crucial. Proper disease manage-
ment may relieve symptoms, prevent hospitalization or
improve survival, but may also affect the patient’s
health-related quality of life (HRQoL). The European
Society of Cardiology (ESC) Task Force produced
guidelines for the diagnosis and management of HF,
intended to be used by clinical practitioners [3].
However, previous studies consistently show an insuf-
ficient uptake of these guidelines in clinical practice
[4]. Of particular concern is the poor implementation
of exercise guidelines [5]: participation rates of HF
patients in cardiac rehabilitation are generally below
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20% in Europe [6]. This calls for action to develop
strategies to give appropriate and effective personal-
ized lifestyle advice to HF patients.
A promising technology for improving disease manage-
ment in HF may be mobile health (mHealth), which en-
compasses the use of mobile devices as a support to clinical
practice. mHealth has already been implemented in HF pa-
tients to provide regular follow-up and physiological moni-
toring, to ensure safety and to detect complications [7]. In
addition, it may be a tool to deliver education and support
patients regarding self-monitoring and self-management.
However, evidence on the effectiveness of this approach in
HF patients has been diverse. A recent meta-analysis sug-
gests clinical benefits on all-cause mortality and heart fail-
ure related hospitalisations [8], but large clinical trials did
not show any effect on readmission or death [9, 10]. How-
ever, the BEAT-HF trial found despite the absence of re-
duced rehospitalization or mortality, an improvement in
HRQoL [11].
HRQoL and perceived health status, both
patient-reported outcomes (PROs), have increasingly been
recognized as outcomes of interest in HF and coronary pa-
tients [12, 13]. PROs are not surrogates for harder end-
points such as mortality, but rather represent independent
outcomes [14]. Nevertheless, some studies report that
HRQoL and health status may be predictive of clinical
events in HF [15, 16], suggesting a relation between both
types of outcome. These findings indicate that patients’
perceptions of worsening symptoms might carry vital prog-
nostic information, and should be implemented in trials
evaluating disease management.
An aspect that has been largely ignored in mHealth tri-
als is the psychological aspect that is necessary to start
changing behaviour and to cope with HF symptoms. Psy-
chological interventions such as cognitive behavioural
therapy and mindfulness exercises have already been
shown to be successful in changing lifestyle behaviour [17,
18] and to significantly reduce anxiety, depression and
clinical symptoms which are common in HF patients [19].
Therefore, implementing psychological interventions in
mHealth technology may offer an added value.
This paper presents the study protocol of HeartMan
(Personal Decision Support System For Heart Failure Man-
agement) which aims to develop a personal health system
to improve disease management and HRQoL in HF. In
this system, patients’ monitoring is focused on their phys-
ical condition and psychological state. This data is inte-
grated into a decision support system (DSS), which is an
information system supporting complex decision making
processes. In HeartMan, the DSS suggests the most ap-
propriate intervention (including exercise, nutrition, medi-
cation and mental support) to modify and manage the
patient’s lifestyle, adapted to his psychological profile in
order to increase adherence to the medical advice.
Study design
Design
HeartMan is a randomized controlled 1:2 (control:inter-
vention) proof-of-concept trial, being conducted across
two countries (Belgium and Italy) to compare standard
care in HF with the addition of a personal mHealth sys-
tem on top of standard care. In each country 60 patients
are enrolled for a six-month period. Hence 40 patients
in total are included in the control group and 80 in the
intervention group.
Study objectives and outcome measures
The overall objective of HeartMan is to improve disease
management, resulting in an improvement in HRQoL
after a 6 months intervention period.
Secondary objectives are the effects of HeartMan on be-
havioural outcomes, illness perception and clinical outcomes
which may impact disease management and HRQoL. Add-
itional secondary aims encompass the effects of psycho-
logical interventions within HeartMan and a user-friendly
design of the HeartMan system.
Primary and secondary outcome measures, which are
assessed in the intervention and control group, are listed
below. These measures are collected at start and end of
the study, unless otherwise stated.
Primary objective
– The primary endpoint is the self-reported improve-
ment in self-care and HRQoL, measured by the Self-
care of Heart Failure Index [20] and Minnesota Liv-
ing with Heart Failure Questionnaire [21]
Secondary objectives
– Effect of HeartMan on behavioural outcomes, which
are:
 Adherence to dietary recommendations,
measured by a self-composed questionnaire on
nutritional knowledge and eating behaviour
 Activity behaviour, daily measured by the number
of calories (via an accelerometer in the HeartMan
wristband sensor)
 Medication adherence by questioning the patient
on their medication intake on a weekly basis
 Sexual activity, assessed with the Sexual
Adjustment Scale [22] and Needs for Sexual
Counselling Scale in chronic HF [23]
– Effect of HeartMan on illness perception, evaluated
with the Brief Illness Perception Questionnaire [24]
– Effect of HeartMan on exercise tolerance, measured by:
 Change in resting heart rate and heart rate
during exercise
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 Distance obtained at the six–minute walking test
(6MWT) [25]
– Effect of psychological interventions in HeartMan –
cognitive behavioural therapy and mindfulness
exercises – on anxiety and depressive feelings,
measured with State Trait Anxiety Inventory [26]
and the Beck Depression Inventory II [27]
– Evaluation of the user experience of HeartMan to
assess the expectations towards the system and the
patient’s experiences (only measured in the
intervention group), evaluated with the Unified Theory
of Acceptance and Use of Technology questionnaire,
[28] adapted to the objectives of the HeartMan system
and to the population of elderly users [29]
Sample size calculation Sample size calculations were
based on primary outcome data from the CHIRON project
[13], showing that 90 patients are needed to show a differ-
ence of 5.8 beats per min in average daily awake heart rate–
as a fundamental parameter correlating with HRQoL – with
90% power between the two groups. In order to account for
possible drop-outs, the trial is performed enrolling 120 pa-
tients – 60 in each of the two participating countries – based
on a 1:2 (control:intervention) randomization protocol.
Study population In order to be eligible for inclusion
the following criteria were used:
– Willing and able to make use of a smartphone and to
give informed consent for participation in the study
– Adults ≥18 years old
– Ischemic or non-ischemic HF disease
– Functional New York Heart Association (NYHA)
class 2–3
– Reduced left ventricular ejection fraction ≤40%
– Ambulatory HF patients in stable condition: at least
one hospitalization due to HF, but no hospitalization
during the month before start of the trial and no
planned surgery
– Good cognitive function, if cognitive impairment is
suspected, the patient will be evaluated with Mini
Mental State Examination (MMSE)
– Sufficient knowledge of the native language (Dutch
in Belgium, Italian in Italy)
HF patients who fulfil the above mentioned criteria
are excluded if:
– They suffer from a concomitant end-stage chronic
kidney disease necessitating haemodialysis
– They are already participating in a disease
management program influencing the HeartMan
intervention
Investigation procedure A general overview of this
study is presented in Fig. 1 and described in detail in fol-
lowing paragraphs.
Recruitment and enrolment Patient recruitment is
organized across three Belgian and one Italian hos-
pital, representing one geographic area in each coun-
try. The participating hospitals in Belgium include
one university hospital (University Hospital Ghent)
and two local hospitals (AZ Maria Middelares Ghent
and OLV Hospital Aalst). In Italy, one local hospital
(Rieti General Hospital) as well as the local health
authority (ASL Rieti) with their general physicians is
involved.
The target population screened for participation are
stable ambulatory HF patients who visit their treating
cardiologist on a regular basis. At the time of consult-
ation, the physician or HF nurse identifies eligible pa-
tients, briefly presents the study and asks about their
interest in participation. If the patient shows interest, he
is asked to come back for a scheduled appointment.
Treating cardiologists and general physicians (for Italy)
may also directly contact an eligible candidate, if the pa-
tient has no planned routine consultation in the imme-
diate future.
Baseline visit After patients have signed the informed
consent form stating their willingness to be random-
ized, a baseline assessment is planned in the hospital
maximum 20 weeks prior to the start of the trial.
During this visit, all patients perform a 6MWT, which
is in line with the recommendations of the Heart
Failure Association of the ESC [5] to evaluate one’s
exercise capacity in case cardiopulmonary exercise
testing (CPET) is not available.
In addition, every participant receives a self-administered
questionnaire package which is filled in during the baseline
assessment. These questionnaires have previously been de-
scribed in the study outcome measures section and details
are listed in Table 1.
Following this assessment, patients are randomized to
the intervention or control group according to a sealed
randomization scheme with two balanced series of 60
envelopes (one for each country), each containing a ran-
dom series of 20 control and 40 experimental numbers.
In order to handle potential early drop-out of patients, a
separate series of 24 sealed and balanced envelopes (12
for each country) is prepared.
Parallel to the baseline assessment, the following param-
eters are retrieved from the medical patient file as an add-
itional base for providing personalized lifestyle advice:
demographic and clinical characteristics, HF-related char-
acteristics and laboratory parameters, risk factors, comor-
bidities, medication use and exercise capacity.
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Intervention Instructions concerning the HeartMan
intervention tool are given to the intervention group
during a home visit.
Intervention equipment
Participants randomized to the intervention group are
equipped with a multi-monitoring health platform
able to monitor, process and fuse physio-psychological
and behavioural data. The main component of the
trial equipment is the HeartMan wristband sensor
developed by BITTIUM (Oulo, Finland). This is an
ambulatory recorder and transmitter for heart rate,
heart rate variability, galvanic skin response, skin
temperature, respiration rate and motion. This
wristband has Bluetooth communication, recording
function, display, haptic interface and the ability to
synchronize with other external devices. Apart from
the HeartMan wristband sensor, the equipment con-
sists of registered and commercially available devices
including a digital bathroom scale (ADE, Model Silje
BE1303), upper arm blood pressure monitor (A&D
Medical, Model Number UA-611) and a pill box or-
ganizer (PuTwo, 7-Day AM/PM Night Reminder
Medi-Planner). Furthermore, a smartphone (Nokia 6
TA_1021) with HeartMan app installed is provided
for the duration of the trial.
Fig. 1 Study flow chart
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Intervention components for the patient
Information coming from the trial equipment, baseline visit
and medical patient file are integrated into the HeartMan
DSS. The major component is personalized lifestyle advice
on nutrition and exercise. The second intervention modal-
ity includes general notifications for medication intake with
possibility to track the weekly consumption. The third
component encompasses cognitive behavioural therapy and
mindfulness exercises, which are offered for treating anxiety
and depressive symptoms and to improve adherence. The
fourth modality are reminders for physician’s appointments,
which can additionally be activated upon the patient’s re-
quest. The fifth intervention element is a graphical presen-
tation of progress and success in following the advice,
designed to improve the patient’s adherence to HF manage-
ment. The last type of intervention component is education
about HF disease and its treatment, which is provided in a
library to be consulted on a voluntary basis. All these differ-
ent types of interventions are delivered by notifications in a
personalized way adapted to the patient’s psychological pro-
file (based on State Trait Anxiety Inventory [26] and Beck
Depression Inventory II [27]).
A detailed overview of these intervention components
is given in Table 2.
Intervention component for the caregiver: Web interface
Apart from functionalities focusing on patient’s disease
management, HeartMan provides valuable information
for formal caregivers. Through a web interface, treating
physicians may check adherence and progress of their
patient by graphical presentations giving an overview of
a certain period of time.
Alert notifications
Once a patient has received the trial equipment and ne-
cessary instructions, the HeartMan app is intended as a
stand-alone application used by the patient, without add-
itional support of the HF nurse. Since HF patients need to
monitor their weight, heart rate and blood pressure on a
regular basis, the HeartMan app will remind them to take
these measurements. Unexpected results in these parame-
ters are not transferred to the hospital but the patient will
get a notification to contact his treating physician. If pre-
defined exercise requirements concerning heart rate or
blood pressure are not met before starting the exercise
program or exceed the predefined limits during exercise, a
similar notification will appear. A helpdesk for technical
questions related to the HeartMan system is available on
weekdays from 9 a.m. until 4 p.m. This may strengthen
the patient’s role in his own disease management. Table 3
presents the cut-off limits of the alert notifications.
Standard care
The HeartMan intervention is provided on top of stand-
ard care which is given to all HF patients, regardless of the
randomization process. Standard care consists of optimal
medical treatment according to the guidelines [3], and
written and oral education on HF disease and its manage-
ment provided by the HF nurse. Regular visits to the treat-
ing physician are scheduled several times per year.
Table 1 Overview of the questionnaire package
Questionnaire Description Number of
items
Subscales
Self – care of Heart Failure Index [20] Self-care 22 Self-care behavior, self-care management, self-care confi-
dence, and symptom perception
Minnesota Living with Heart Failure
Questionnaire [21]
Health – related
quality of life
21 Physical, socio-economic, and emotional/psychological
aspects
Brief Illness Perception Questionnaire [24] Illness perception 9 Cognitive representation, emotional representation, illness
comprehensibility, and perceived cause of illness
Sexual Adjustment Scale [22] (subscale of
the Psychosocial Adjustment Scale)
Sexual activity 6 Relationship and sexuality
Needs for Sexual Counseling Scale in
Chronic Heart Failure [23]
Sexual activity 21 Symptoms, medication and information, relaxation,
relationship, and psychological factors
State Trait Anxiety Inventory [26] Anxiety 40 State anxiety scale (s-anxiety) and trait anxiety scale (t-anxiety)
Beck Depression Inventory II [27] Depression 21 Depression and anxiety
Unified theory of acceptance and use of
technology questionnaire [28]
User expectations and
user experience
37 /
Self – composed questionnaire on
nutritional behavior
Nutritional behavior 24 Drinking behavior and eating behavior
Self – composed questionnaire on
nutritional knowledge
Nutritional knowledge 12
(14: patients
with diabetes)
Knowledge about heart failure (and diabetes) nutrition
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Table 2 Overview of the HeartMan intervention components
Intervention
component
Strategy Description of the intervention
Nutrition Education on:
- knowledge of healthy
nutrition
- eating behavior
- Questionnaire to evaluate knowledge and healthy behavior
○ Baseline and end of the trial
- Personalized feedback and education is coupled to the questionnaire
- Possibility to consult questionnaire and education material via the application on a voluntary
basis during the trial
Exercise Endurance exercise - Assessment of physical capacity: cyclo-ergometry (if available) and 6MWT
- Differentiation based on baseline physical capacity level (low level: cyclo-ergometry < 1 W/kg
or 6MWT < 300 m vs. normal level: ≥1 W/kg or 6MWT ≥300 m)
- Individual exercise program via the application:
○ Frequency: 2–5 times per week
○ Intensity: HR rest + 40–70% HRR or RPE 10–14/20
○ Time: 10-40 min
○ Type: cycling, walking, steps
- Individual progress:
○ Increase in frequency or time after a predefined number of weeks (after patient’s approval)
○ Increase in intensity if following criteria are met:
• Adherence to exercise therapy > 60% of training sessions
• Not overshooting the target heart rate in 80% of the training sessions
• Patient’s subjective opinion of exercise intensity: ‘no discomfort’ in 80% of the training
sessions
• After at least 8 weeks of exercise training
Resistance exercise - Differentiation based on baseline physical capacity level
- Individual exercise program via the application:
○ Frequency: 2–3 times per week
○ Intensity: 60–70% 1Repetition maximum
○ Time: 1–2 sets per day
○ Type: dynamic upper and lower limb exercises, with no or light weights
- Individual progress:
○ Increase in frequency or time after a predefined number of weeks (after patient’s approval)
○ Increase in intensity (from no weights to light weights) after a predefined number of weeks
(after patient’s approval)
Medication intake Weekly pill organizer - Passive pill dispenser, with personalized reminder function in HeartMan application:
○ Guidance to prepare medication once per week
○ Daily personalized notifications to remind the patient to take his medication at the right time
- Assessment of medication adherence by a weekly question whether the patient has taken the
recommended medication or not
Appointments - Personalized reminder function in HeartMan application 1 day before the appointment (only
upon the patient’s request)
Mental support Cognitive behavioral
therapy
- Patient profiling: adaption of the communication according to the psychological profile
(anxious, depressed or low motivation) in order to increase adherence to lifestyle
interventions
Mindfulness exercises - Mindfulness exercises are offered to the patient on a daily basis, adapted to the patient’s
profile (anxious, depressed or motivated).
- Different types of exercises:
○ Listening
○ Focusing
○ Awareness
○ Games
Disease education
(illness perception)
Education on:
- Heart failure disease:
causes, symptoms
- Pharmacological
treatment:
indications, common side
effects
- Sexual dysfunction and
sexual activity
- Written education in a depository
- To consult on a voluntary basis
6MWT, six-minute walking test; HR, heart rate; HRR, heart rate reserve; RPE, rating of perceived exertion
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End-of-study visit
The intervention is terminated after using the system for
three to six months. At this time, all participants from the
intervention and control group undergo the end-of-study
examination in the hospital that entails the same question-
naires and tests as during the baseline visit.
Statistical analysis
The main analysis of primary and secondary endpoints
will be based on the Intention-To-Treat principle, i.e.
including all patients in the analysis who did not drop
out within the first 4 weeks of the trial. In order to as-
sess the clinical effect of the HeartMan intervention on
the different outcomes, an additional per-protocol ana-
lysis will be performed in patients who adhere to the
treatment plan for at least 50%. Based on these results,
a dose-response analysis will be conducted to verify the
relation between the level of adherence and interven-
tion effects.
Prior to each analysis, distribution of the variables will
be checked in order to choose correct statistical tests
and identify outliers. In all analyses, p values < 0.05 will
be considered to be statistically significant.
Effects of the proof-of-concept trial will be assessed
by analysing baseline and end-of-investigation data
between and among treatment groups. The primary
endpoint of the HeartMan project is the self-reported
improvement in HRQoL. First, T-tests or its
non-parametric variant and chi-square tests will be used
to compare the characteristics between the groups.
Next, in order to assess the effect of the intervention
among the different groups, a repeated measures design
with time*group interaction effect will be chosen. A
similar statistical approach will be performed for the
secondary analyses.
Handling missing data
A great effort will be made to have complete data on
outcome measures and to use all obtained information.
For early drop-out within 4 weeks after starting the
intervention, novel candidates will be foreseen.
For those who drop out in a later phase, efforts will be
made to perform the end-of-study examination and if
not feasible, these will be considered as missing data. In
the case of missing data, some of the outcome measures
(e.g. heart rate or blood pressure) can be retrieved
through data from the HeartMan system, using the Last
Observation Carried Forward (LOCF) principle.
Discussion
HeartMan aims to provide appropriate and comprehensive
guidance on different domains of disease management in
HF, tailored to the patient’s medical and psychological pro-
file. This approach is intended to have a positive impact on
HRQoL, which is the primary outcome of this trial.
The focus on HRQoL as a primary outcome instead of
targeting hard outcomes such as mortality and
hospitalization is one of the innovative approaches in com-
parison with previous mHealth studies. [8–10] HRQoL has
gained more attention lately, often as a secondary outcome
[11], although it also becomes more prominent as a primary
outcome in recent studies [13].
Results on the effectiveness of mHealth technologies are
rather mixed. Plausible reasons may be the focus on a single
intervention modality (e.g. education) or a lack of patient’s
adherence to technology. In HeartMan, the combination of
different intervention modalities, adapted to the individual
patient’s physical and psychological condition, is a unique
approach, which makes HeartMan stand out from related
projects. Another aspect that may increase the likelihood of
successful adherence is the involvement of patients in the
Table 3 Alert notifications
Parameter Device Frequency, time Alert notification
Weight Scale - weekly measures at rest
• daily or twice a week (configurable by physician)
• before breakfast
≥2 kg weight gain in 3 (or less) days
Systolic BP BP monitor - weekly measures at rest
• twice a week
• after breakfast and 10 min of resting
- pre-exercise requirement
> 180 or < 90 mmHg
> 180 or < 90 mmHg
Diastolic BP BP monitor - weekly measures at rest
• twice a week
• after breakfast and 10 min of resting
> 100 or < 55 mmHg
Heart rate HeartMan wristband - weekly measures at rest
• twice a week
• after breakfast and 10 min of resting
- pre-exercise requirement
> 120 or < 40 bpm
> 120 or < 40 bpm
Respiratory rate HeartMan wristband - weekly measures at rest
• twice a week
• after breakfast and 10 min of resting
> 24 or < 10 breaths per min
BP blood pressure, bpm beats per minute
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designing process of HeartMan, making it more adapted to
the patient’s daily life.
HeartMan is aimed at evaluating the overall impact of
the various active interventions on HRQoL. An analysis of
the separate effects of the different intervention compo-
nents will however not be possible due to the design of the
current trial. This may be done in the future with specific-
ally designed trials in case the present trial may succeed.
The HeartMan trial will be implemented in two countries,
which will allow us to gain more insight into the use of
HeartMan across different cultures. However, the minor
differences in the recruitment process may create a selec-
tion bias which has to be investigated in a post-hoc analysis.
This study is a proof-of-concept trial, which may lead to
preliminary study results and a limited generalizability.
Nevertheless, these results may serve as a basis for larger
studies in the future. A barrier that may also affect the
generalizability is the exclusion of HF patients with
end-stage chronic kidney disease or severe cognitive im-
pairment. The reason for excluding these patients is the
physical and cognitive demand of the HeartMan interven-
tion, making participation difficult. Finally, this type of
intervention with the use of new technologies including a
smartphone may make involvement for elderly patients
challenging, but a careful design adapted to the user’s per-
spective together with home visits and a help desk for tech-
nical support should make participation feasible even for
this elderly population.
In conclusion, HeartMan is technologically the most
innovative HF self-management support system to date.
This trial will provide evidence whether modern
mHealth technology, when used to its full extent, can
improve HRQoL in HF.
Trial status
The HeartMan trial is actively enrolling participants at
the moment of manuscript submission.
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